An injectable gel that solidifies within the body to deliver a drug
AI-generated hypothesis · Pre-publication · To be tested experimentally
Table of contents — full brief
- Hypothesis and mechanismCausal chain, key assumptions, residual unknowns
- State of the artVerified references and counter-evidence (DOIs)
- Falsifiable predictionsQuantitative bounds, statistical tests, H0
- Experimental protocolThree phases — in silico → minimal → full
- Impact analysisNovelty, residual gaps, available data
- Panel reviewFive personas + meta-review
Verified references
5 of 9 references- DOI: 10.1021/acsami.9b04979 ↗
Injectable Click-Crosslinked Hyaluronic Acid Depot To Prolong Therapeutic Activity in Articular Joints Affected by Rheumatoid Arthritis.
2019 - DOI: 10.1002/anie.202421713 ↗
In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy.
2024 - DOI: 10.26434/chemrxiv.11383659 ↗
Bioorthogonal Tetrazine Carbamate Cleavage by Highly Reactive Trans-Cyclooctene.
2019 - DOI: 10.1021/ACS.CHEMMATER.9B00769 ↗
In Situ Forming, Dual-Crosslink Network, Self-Healing Hydrogel Enabled by a Bioorthogonal Nopoldiol–Benzoxaborolate Click Reaction with a Wide pH Range
2019 - DOI: 10.1021/acs.bioconjchem.0c00216 ↗
In situ one-step fluorescence labeling strategy of exosomes via bioorthogonal click chemistry for real-time exosome tracking in vitro and in vivo.
2020
+ 4 more references
Detailed panel scores
An excellent three-phase falsification architecture (in silico → in vitro → in vivo) is presented, with clear and quantitative GO/NO-GO/PIVOT criteria. This design permits early termination of the protocol if the underlying hypotheses are not verified, thereby conserving resources and reducing animal use.
The hypothesis is supported by a well-characterised bioorthogonal chemistry (Tz/TCO IEDDA) with high second-order rate constants (k₂_obs > 10² M⁻¹s⁻¹), which is consistent with the literature and constitutes a solid starting point for rapid in situ gelation.
The bioorthogonal Tz/TCO chemistry is indeed rapid and selective in solution, providing a solid kinetic basis for gelation.
The clear and immediate addressable market is interventional oncology (chemoembolisation, image-guided tumour resection) and regenerative medicine (bone/cartilage defect filling), which represent a combined TAM of approximately $4.2B by 2028, with an unmet need for injectable depots exhibiting controlled release kinetics and no cytotoxic by-products.
The hypothesis is presented as clear and falsifiable, with an experimental design structured in three phases (in silico, in vitro, in vivo) that aligns precisely with the expectations of ERC/ANR reviewers in terms of rigour and risk reduction.
Receive the next SPORE hypotheses
Once or twice a month, in your inbox. No spam, one-click unsubscribe.
Your data stays private. No third-party sharing. GDPR-compliant.